Stock Research: Bristol-Myers Squibb

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Bristol-Myers Squibb

NYSE:BMY US1101221083
30
  • Value
    27
  • Growth
    34
  • Safety
    Safety
    94
  • Combined
    49
  • Sentiment
    22
  • 360° View
    360° View
    30
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering medicines for serious diseases. It operates in oncology, hematology, immunology, and neuroscience. The company operates globally. In the last fiscal year, the company had a market cap of $94,489 million, profits of $36,351 million, revenue of $48,300 million, and 34,100 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 30 (better than 30% compared with alternatives), overall professional sentiment and financial characteristics for the stock Bristol-Myers Squibb are below the industry average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Bristol-Myers Squibb. Only the consolidated Value Rank has an attractive rank of 94, which means that the share price of Bristol-Myers Squibb is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is lower than for 94% of alternative stocks in the same industry. All other consolidated ranks are below average. The consolidated Growth Rank has a low rank of 34, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. The consolidated Safety Rank has a riskier rank of 27, meaning the company has a riskier financing structure than 73% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, professionals are more pessimistic about the stock than for 78% of alternative investment opportunities, reflected in the consolidated Sentiment Rank of 22. ...read more

more
Index
Dividends USA
Diversity USA
D.J. US Pharmaceutical
S&P 500
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 30-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
94 92 92 97
Growth
34 43 7 27
Safety
Safety
27 30 31 35
Sentiment
22 40 68 51
360° View
360° View
30 51 39 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
5 9 10 34
Opinions Change
6 12 48 64
Pro Holdings
n/a 88 87 40
Market Pulse
51 79 78 68
Sentiment
22 40 68 51
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
94 92 92 97
Growth
34 43 7 27
Safety Safety
27 30 31 35
Combined
49 58 29 52
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
86 83 91 96
Price vs. Earnings (P/E)
52 43 37 40
Price vs. Book (P/B)
29 23 19 35
Dividend Yield
98 98 98 98
Value
94 92 92 97
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
1 6 25 11
Profit Growth
98 100 31 47
Capital Growth
30 17 26 48
Stock Returns
30 61 37 73
Growth
34 43 7 27
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
13 16 24 34
Refinancing
28 27 25 25
Liquidity
72 75 76 66
Safety Safety
27 30 31 35

Similar Stocks

Discover high‑ranked alternatives to Bristol-Myers Squibb and broaden your portfolio horizons.

Cognizant Technology

NasdaqGS:CTSH
Country: USA
Industry: IT Consulting & oth. Services
Size: X-Large
Full Stock Analysis

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

TEGNA

NYSE:TGNA
Country: USA
Industry: Broadcasting
Size: Medium
Full Stock Analysis

PriceSmart

NasdaqGS:PSMT
Country: USA
Industry: Hypermarkets, Super Centers
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.